Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.

1 Jun 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma.

29 May 2015

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology.

21 May 2015

First-line axitinib ‘feasible’ in advanced, metastatic RCC

A Japanese single-institution study suggests that axitinib may be a feasible first-line option for patients with locally advanced or metastatic renal cell carcinoma.

21 May 2015

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Argos is developing AGS-003, which is a fully personalized immunotherapy designed to induce a durable memory T-cell response specific to each patient’s cancer...

14 May 2015

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015.

22 Apr 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates.

20 Apr 2015

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

10 Apr 2015

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests.

25 Mar 2015

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds.

25 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Researchers develop noninvasive method to detect kidney cancer early

If kidney cancer is diagnosed early — before it spreads — 80 percent of patients survive. However, finding it early has been among the disease's greatest challenges.

20 Mar 2015

Study reveals conclusive results in reducing toxicities for Asian patients with mRCC

A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.

19 Mar 2015

Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.

2 Mar 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

SNPs predict sunitinib outcome in mRCC

‘Real-world’ sunitinib findings support trial results

RCC benefit independent of sorafenib, sunitinib sequence order

First-line axitinib ‘feasible’ in advanced, metastatic RCC

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Limited anticancer role for preoperative statins in localised RCC setting

IMDC prognostic model valid in second-line RCC therapy

Alternating sunitinib, everolimus not supported in advanced RCC

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Researchers develop noninvasive method to detect kidney cancer early

Study reveals conclusive results in reducing toxicities for Asian patients with mRCC

Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in